This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teleflex (TFX) to Report Q3 Results: What to Know Ahead of the Release
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Medical Product Stocks Set to Outpace Q3 Earnings Estimates
by Indrajit Bandyopadhyay
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.
Why Edwards Lifesciences (EW) Could Beat Earnings Estimates Again
by Zacks Equity Research
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of TAVR and a solid balance sheet.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Do Options Traders Know Something About Edwards Lifesciences (EW) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Edwards Lifesciences (EW) stock based on the movements in the options market lately.
Edwards Lifesciences (EW) Down 9.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Amazon.com, Cisco Systems, The Southern Company, Edwards Lifesciences and Ross Stores
by Zacks Equity Research
Amazon.com, Cisco Systems, The Southern Company, Edwards Lifesciences and Ross Stores are part of the Zacks top Analyst Blog.
Top Analyst Reports for Amazon.com, Cisco Systems & Southern Company
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Cisco Systems, Inc. (CSCO) and The Southern Company (SO).
Edwards Lifesciences (EW) Rides on TAVR Amid Rise in Costs
by Zacks Equity Research
Edwards Lifesciences' (EW) Surgical Structural Heart business growth is driven by increased penetration of its premium RESILIA products across all regions.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Bruker (BRKR) Q2 Earnings and Revenues Top, '23 Sales View Up
by Zacks Equity Research
Bruker (BRKR) delivers better-than-expected earnings and revenues in the second quarter of 2023.
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.
Acadia Healthcare (ACHC) Q2 Earnings Beat on Higher Admissions
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q2 results indicate improved patient days and revenue per patient day. Management expects 2023 adjusted EPS of $3.25-$3.50.
Edwards Lifesciences (EW) Q2 Earnings Top Estimates, View Up
by Zacks Equity Research
The growing adoption of the PASCAL Precision system in Europe and the United States and Edwards' premium products across all regions have driven Edwards Lifesciences' (EW) Q2 revenues.
Compared to Estimates, Edwards Lifesciences (EW) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Edwards Lifesciences (EW) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.54% and 1.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q2 Earnings Due on Jul 26: DGX, TMO and More
by Urmimala Biswas
MedTech companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how DGX, TMO, EW and ALGN fare this time.
AVNS vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
AVNS vs. EW: Which Stock Is the Better Value Option?
Analysts Estimate Integer (ITGR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business.